The future of cancer immunotherapy: microenvironment-targeting combinations

Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer a...

Full description

Saved in:
Bibliographic Details
Published in:Cell research Vol. 30; no. 6; pp. 507 - 519
Main Authors: Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.
Format: Journal Article
Language:English
Published: Singapore Springer Singapore 01.06.2020
Nature Publishing Group
Subjects:
ISSN:1001-0602, 1748-7838, 1748-7838
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer and its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories of approaches to the design of novel drugs and combination therapies: the first involves direct modification of the tumor, while the second indirectly enhances immunogenicity through alteration of the microenvironment. By systematically addressing the factors that mediate resistance, we are able to identify mechanistically-driven novel approaches to improve immunotherapy outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1001-0602
1748-7838
1748-7838
DOI:10.1038/s41422-020-0337-2